Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-3: Repotrectinib vs Crizotinib in ROS1-positive NSCLC
NCT06140836Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2023
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 21
01
Overview
A Phase 3 trial of repotrectinib in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Dec 2023; status: active, not recruiting.
02
Drugs
repotrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06140836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140836.